Loading...
NASDAQ: TECH
Bio-Techne Corporation
Healthcare · Biotechnology
●S&P 500 since 2021
Market Cap
$8.03B
52w High
$72.16
52w Low
$46.01
P/E
98.63
Volume
214.85K
Outstanding Shares
156.45M
Company profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.
CEOKim Kelderman
SectorHealthcare
IndustryBiotechnology
Employees3,100
IPO dateFeb 9, 1989
Valuation
Forward P/E—
EV/EBITDA38.67
Enterprise value$8.39B
Stock splits
Nov 30, 20224:1
Dec 4, 20002:1
Nov 18, 19972:1
Profitability & growth
Revenue growth-0.39%
Gross margin65.22%▼2.43%vs FY2024
Operating margin9.62%▼52.98%vs FY2024
ROE3.83%▼52.92%vs FY2024
Analyst consensus
RatingBuy
Target price$69.33▲35.07%
18
Buy
7
Hold
0
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
View
EPS
Actual vs estimate by quarter
Q4FY25
ActualEst.
$0.53
$0.50
Q1FY26
ActualEst.
$0.42
$0.42
Q2FY26
ActualEst.
$0.46
$0.43
Q3FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q4FY25
ActualEst.
$316.96M
$294.63M
Q1FY26
ActualEst.
$286.56M
$291.32M
Q2FY26
ActualEst.
$295.88M
$316.59M
Q3FY26
Next Est.
—